Compare Cadence Design Systems Inc (CDNS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cadence Design Systems Inc vs Neurocrine Biosciences Inc — how do they compare? Cadence Design Systems Inc trades at $326.51 (market cap $90.20B), while Neurocrine Biosciences Inc trades at $151.75 (market cap $16.46B). The key difference: Cadence Design Systems Inc is far larger — about 5.5× Neurocrine Biosciences Inc's market cap. Which is the better fit depends on your goals.
| CDNS | NBIX | |
|---|---|---|
Market Cap | $90.20B | $16.46B |
Sector | Technology | Health |
52-Week High | $416.39 | $185.50 |
52-Week Low | $265.66 | $123.10 |
Enterprise Value | $91.41B | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
